Last reviewed · How we verify
Ritalin-SR
At a glance
| Generic name | Ritalin-SR |
|---|---|
| Sponsor | Janssen-Ortho Inc., Canada |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (PHASE2)
- Methylphenidate and Response to Alcohol Cues Pilot Study (EARLY_PHASE1)
- Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer (PHASE2)
- Methylphenidate and Response to Alcohol Cues (PHASE2)
- TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease (EARLY_PHASE1)
- Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints (PHASE4)
- Treating Young Children With Attention Deficit Hyperactivity Disorder (PHASE4)
- Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ritalin-SR CI brief — competitive landscape report
- Ritalin-SR updates RSS · CI watch RSS
- Janssen-Ortho Inc., Canada portfolio CI